Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

(NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal ...

In recognition of National Kidney Health Month, Halton Healthcare is the first regional hospital to offer renal (kidney) ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

(Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal ...

AI-driven tumor mapping with Unfold AI helps doctors more accurately assess prostate cancer size, improving treatment success ...

“Our resources are now focused on the completion of the FULCRUM-VT Pivotal IDE trial and subsequent premarket approval of the VT Cryoablation System with vCLAS™ catheter from the U.S. Food and Drug ...